Navigation Links
People With Diabetes May Have All-Natural Citrus Supplement To Help Lower Blood Glucose and Cholesterol Levels
Date:4/9/2008

KGK Synergize Inc. presents Diabetinol(TM), test results

SAN DIEGO, April 9, 2008 /PRNewswire/ -- Two new studies presented at the Experimental Biology Annual Meeting suggest that an all-natural dietary supplement made from citrus may help people with type 2 diabetes lower their blood glucose numbers after a meal and their LDL-cholesterol levels.

Mal Evans, DVM, MSc, PhD, KGK Synergize Inc.'s Scientific Director, said, "Our scientifically validated testing has consistently shown that Diabetinol(TM) improves blood glucose numbers. This time we saw a sizeable change in glucose intolerance in just a short time. This is good news for many of the 21 million Americans with diabetes. Tighter blood sugar control may mean less diabetic complications like nerve pain and kidney disease. And, that could mean less disability and expense from complications and associated medications and certainly less stress for the patient.

"Although there were no statistically significant changes in fasting blood glucose levels in either group, the Diabetinol(TM)-treated subjects demonstrated an excellent favorable downward trend in their hemoglobin A1C levels. These results suggest that when administered to people with type 2 diabetes over a longer treatment period, Diabetinol(TM) significantly improves glucose tolerance or the blood glucose numbers following a meal.

"Additionally, the Diabetinol(TM)-treated group showed improvements in LDL-cholesterol levels. An elevated LDL-cholesterol level is a risk factor for heart disease, and having type 2 diabetes increases an individual's risk for developing heart disease two to four times. In fact, sixty-five percent of deaths from diabetes are related to cardiovascular causes such as heart attack and stroke," said Evans.

Hemoglobin A1C is an indicator of average blood glucose control over two to three months and is correlated to an individual's risk of developing diabetic complications such as diseases of the eye, kidney and nerves.

In a pilot study, twenty adults with diabetes who were taking oral diabetes medications were randomly assigned to receive either Diabetinol(TM) or a placebo twice per day for three months. Each subject had mildly to moderately elevated cholesterol levels at the start of the study as well.

After 84 days, the group receiving Diabetinol(TM) showed a significant 19 percent reduction in glucose intolerance measured as peak changes in blood glucose over the four hours of a standard oral glucose challenge. The placebo group showed no significant improvements in glucose intolerance. A standard glucose challenge involves ingesting 100 grams of glucose and having blood glucose measurements after 30 minutes and hourly for four hours. Neither the investigators nor the volunteers knew who was receiving the Diabetinol(TM) or the placebo.

The number of Americans with diabetes has been increasing as obesity rates continue to rise. At least 90% of Americans with diabetes have type 2 diabetes. In type 2 diabetes, the body either produces too little insulin or the cells do not respond properly to the insulin and leave the cells starved for energy while raising the blood glucose level.

Earlier animal studies led researchers to test Diabetinol(TM) in humans. Twelve hamsters were treated with a special high-fructose diet to induce diabetes-like symptoms including increased blood glucose, insulin, cholesterol and triglyceride levels. Half of the animals were then given Diabetinol(TM) for 42 days. The other six hamsters were given no anti-diabetic treatment. At the end of the study, the Diabetinol(TM)-treated animals showed improvements in each blood glucose, insulin, and cholesterol and triglyceride levels.

Taken together, these studies suggest that Diabetinol(TM) may help lower blood glucose levels and be beneficial in lowering the risks of heart disease and diabetic complications in people with type 2 diabetes.

An additional six-month study is underway to evaluate Diabetinol(TM) treatment in a larger sample of people with type 2 diabetes.

About KGK Synergize Inc.:

KGK Synergize provides contract research services to the health nutrition, biotechnology and pharmaceutical industries, which include analytical chemistry, in vitro assays, in vivo models, toxicology and human clinical trials.

In addition to its contract research capabilities, KGK has a Product Development Division which brings new and innovative natural health products to the point where they are ready to be manufactured and marketed. These products include Sytrinol(TM) for cardiovascular health, Diabetinol(TM) for the treatment and/or prevention of Type II Diabetes, and Dermytol(TM), a new product for the protection of sun damage to the skin.


'/>"/>
SOURCE KGK Synergize Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. New Resource Available for People With Lymphoma
2. 38.7 Million People Break Guinness World Record for Stand Up Speak Out on International Day for the Eradication of Poverty
3. LAP-BAND(R) System Weight-Loss Surgery Associated With More Than 70 Percent Reduced Risk of Death in People With Severe Obesity
4. Treating Depression Prolongs Life for Older People with Diabetes
5. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
6. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
7. The Heart, Diabetes, And Weight Loss Centers of New York Introduce the New Science of Metabolic Diagnosis and Weight Management
8. Isis Initiates Phase 1 Study of ISIS 325568 Targeting Glucagon Receptor to Treat Type 2 Diabetes
9. Diabetes Research Institute Invention Promotes Growth of Stem Cells into Insulin-Producing Cells
10. Cleveland Clinic Study Shows the Diabetes Drug Pioglitazone Reduces Risk of Death, Heart Attack and Stroke, but Increases Risk of Heart Failure
11. ACTOS(R) (pioglitazone HCl) Demonstrates Reduced Risk of Ischemic Cardiovascular Disease in Patients with Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2019)... Calif. (PRWEB) , ... November 19, 2019 , ... HashCash ... for DNA sequencing, as part of a genome research initiative for precision drugs. , ... data. It will ensure that patients and contributors have more control over their genome ...
(Date:11/16/2019)... ... November 15, 2019 , ... Leading ... http://www.medshift.com . The new site features a modern design, enhanced functionality, ... navigate service offerings. , “The company has expanded rapidly since its inception and ...
(Date:11/15/2019)... ... November 15, 2019 , ... Unlike fine wine, shoulder ... notably, shoulder impingement syndrome and rotator cuff disease – rise after age 50, says ... upper limbs. , Impingement syndrome occurs when the uppermost tendon of the rotator cuff ...
Breaking Medicine Technology:
(Date:11/16/2019)... ... November 15, 2019 , ... ... with memory impairment, has announced the Best Memory Care Facilities in Amarillo, Texas. ... facility features and amenities. , According to the Alzheimer’s Association , ...
(Date:11/15/2019)... Tenn. (PRWEB) , ... November 15, 2019 , ... ... be hosting a complimentary webinar on comprehensive school physical activity programs (CSPAP) on ... architects, architects, planners, and recreation and park professionals, this one-hour and 15-minute webinar ...
(Date:11/14/2019)... , ... November 14, 2019 , ... ... at Loma Linda University International Heart Institute have performed a pioneering ... access from the axillary artery in the shoulder. The new procedure offers surgeons ...
(Date:11/14/2019)... ... 2019 , ... AstraZeneca and MSD (Merck) announced today that ... of its application for the MEK inhibitor selumetinib, for use in patients with ... FDA’s acceptance of the application is a major milestone for selumetinib becoming the ...
(Date:11/12/2019)... ... November 12, 2019 , ... InteliChart, the leader in ... Tidewater Physicians Multispecialty Group (TPMG), a network of 220 providers across 85 ... platform to deliver enhanced patient experience and overall engagement to their patients. ...
Breaking Medicine News(10 mins):